BIOCORRX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 USD | -8.54% |
|
-48.98% | -3.85% |
| 04-03 | BioCorRx Inc. Announces Board Resignations | CI |
| 04-01 | BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 214K 292K | Sales 2023 | 89.16K 122K | Capitalization | 6.75M 9.23M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -5.47M | Net income 2023 | -3M -4.1M | EV / Sales 2022 | 42.5 x |
| Net Debt 2022 | 1.61M 2.2M | Net Debt 2023 | 1.75M 2.39M | EV / Sales 2023 | 95.3 x |
| P/E ratio 2022 |
-1.61
x | P/E ratio 2023 |
-1.73
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.01% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -8.54% | ||
| 1 week | -48.98% | ||
| Current month | -16.20% | ||
| 1 month | -16.67% | ||
| 3 months | +1.35% | ||
| 6 months | -53.12% | ||
| Current year | -3.85% |
1 week
0.68
1.48
1 month
0.681.50
Current year
0.671.50
1 year
0.672.22
3 years
0.229.98
5 years
0.009.98
10 years
0.0034.00
| Managers | Title | Age | Since |
|---|---|---|---|
Lourdes Felix
CEO | Chief Executive Officer | 56 | 12-09-30 |
Kent Emry
CHM | Chairman | 55 | 13-09-12 |
Louis Lucido
PSD | President | 75 | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Louis Lucido
PSD | President | 75 | 19-02-28 |
Joe Galligan
BRD | Director/Board Member | 64 | 19-03-31 |
Luisa Ingargiola
BRD | Director/Board Member | 56 | 19-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.75 | -8.54% | 902 |
| 24-04-24 | 0.82 | +9.33% | 7,500 |
| 24-04-22 | 0.75 | -48.98% | 4,172 |
Delayed Quote OTC Markets, April 26, 2024 at 11:36 am
More quotes
BioCorRx Inc., through its subsidiaries, develops and provides addiction treatment solutions for the treatment of substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The Company, through its subsidiary, BioCorRx Pharmaceuticals Inc., is engaged in the development of BICX104, a subcutaneous implantable naltrexone pellet for the treatment of both opioid and alcohol use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.85% | 6.67M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- BICX Stock
